Krebs Biochemicals & Industries Limited Stock Price Today (NSE: KREBSBIO)
Fundamental Score
Krebs Biochemicals & Industries Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Krebs Biochemicals & Industries Limited share price today is ₹64.89, up +1.26% on NSE/BSE as of 19 June 2026. Krebs Biochemicals & Industries Limited (KREBSBIO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹141.35 (Cr). The 52-week high for KREBSBIO share price is ₹91.90 and the 52-week low is ₹38.33.
Krebs Biochemicals & Industries Limited Share Price Chart — NSE/BSE Historical Performance
Krebs Biochemicals & Industries Limited share price chart: 14.48% return over the past month. 52-week high ₹91.90, 52-week low ₹38.33.
Krebs Biochemicals & Industries Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹64.21 | ₹65.00 | ₹63.00 | ₹64.89 | 1.51K (Cr) | |
| ₹64.00 | ₹68.40 | ₹64.00 | ₹64.08 | 5.89K (Cr) | |
| ₹68.00 | ₹71.25 | ₹64.75 | ₹65.16 | 23.98K (Cr) | |
| ₹66.90 | ₹68.14 | ₹65.22 | ₹68.14 | 37.42K (Cr) | |
| ₹64.00 | ₹64.90 | ₹63.00 | ₹64.90 | 17.98K (Cr) | |
| ₹61.75 | ₹61.81 | ₹60.01 | ₹61.81 | 8.13K (Cr) | |
| ₹56.07 | ₹58.87 | ₹55.00 | ₹58.87 | 11.53K (Cr) | |
| ₹56.39 | ₹57.00 | ₹54.32 | ₹56.07 | 1.78K (Cr) | |
| ₹57.91 | ₹57.91 | ₹55.02 | ₹55.16 | 16.23K (Cr) | |
| ₹56.20 | ₹57.98 | ₹56.20 | ₹57.91 | 47.00 (Cr) |
Krebs Biochemicals & Industries Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹64.00 | ₹68.40 | ₹63.00 | ₹64.89 | +1.39% | |
| ₹59.38 | ₹71.25 | ₹54.32 | ₹65.16 | +9.73% | |
| ₹43.00 | ₹68.58 | ₹40.00 | ₹59.67 | +38.77% | |
| ₹56.30 | ₹56.98 | ₹38.33 | ₹39.75 | -29.40% | |
| ₹59.78 | ₹62.80 | ₹54.00 | ₹57.04 | -4.58% | |
| ₹71.80 | ₹73.01 | ₹53.05 | ₹58.82 | -18.08% | |
| ₹67.40 | ₹76.85 | ₹63.60 | ₹69.04 | +2.43% | |
| ₹73.00 | ₹73.00 | ₹64.16 | ₹67.40 | -7.67% | |
| ₹71.80 | ₹74.70 | ₹65.55 | ₹69.04 | -3.84% | |
| ₹73.89 | ₹82.49 | ₹69.80 | ₹70.63 | -4.41% | |
| ₹77.00 | ₹81.35 | ₹70.34 | ₹71.25 | -7.47% | |
| ₹87.80 | ₹90.88 | ₹75.50 | ₹78.39 | -10.72% |
AI Research Briefing
Powered by Gemini · 2026-04-09
A speculative microcap API play with a broken balance sheet and regulatory headwinds.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Krebs Biochemicals saw its stock hit a 20% upper circuit to on April 7th. However, the exchange has sought clarification from the company on April 8th regarding significant price movement. The company also filed its SEBI compliance certificate for Q4FY26. Trading window closed on March 31, 2026.
CORE STORY (THE REAL GAME)
A low-quality microcap API play, subject to regulatory risk and volatile price swings. Market participants are likely gambling on a turnaround driven by API tailwinds.
- Upper circuit driven by speculative buying
- Positive API sector sentiment
- SEBI compliance filings
- Vizag unit restarts operations
- Significant API order wins
- Successful debt restructuring
- Microcap liquidity risk
- Negative equity
- Vizag unit closure
Promoter holding is high at 72.74%, but no recent change. FII/DII negligible.
Indian pharma exports are growing, but global pricing pressures exist.
No. Free Cash Flow 5Y is ₹-132.65 Cr.
Near-term outlook is highly uncertain, dependent on Vizag unit restart and API demand. Long-term viability is questionable.
Primary Thesis Risk
Continued Vizag unit closure will bankrupt the company.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Krebs Biochemicals & Industries Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Krebs Biochemicals & Industries Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KREBSBIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.74%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Suboptimal ROCE (-30.09%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-35.14%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-67.57%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (4.02% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (1.23% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-3.19x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-132.65 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.50%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Krebs Biochemicals & Industries Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Krebs Biochemicals & Industries Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Krebs Biochemicals & Industries LimitedKrebs Biochemic...Selected✓ KREBSBIO • 524518 | 11.4/100 | ₹64.89₹65 | ₹141.35₹141.35 | — — | — — | -30.09%Poor -30.09% Poor | — — | 1.23%Average 1.23% Average | 5.33%Good 5.33% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Krebs Biochemicals & Industries Limited Quarterly Performance
Latest quarterly metrics for KREBSBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-67.57%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-6.60%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.33%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
1.23%
Compounded annual net profit growth over 5 years
Krebs Biochemicals & Industries Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KREBSBIO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Krebs Biochemicals & Industries Limited Financial Statements
Annual income statement, balance sheet and cash flow for Krebs Biochemicals & Industries Limited (KREBSBIO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Krebs Biochemicals & Industries Limited
About KREBSBIO (Krebs Biochemicals & Industries Limited)
Krebs Biochemicals & Industries Limited is a pioneering force in the pharmaceutical landscape of India, dedicated to the intricate art of crafting active pharmaceutical ingredients... (APIs). With a resolute commitment to advancing healthcare, KREBSBIO meticulously engineers biotech processes that transcend the conventional, finding vital applications not only in medicine but also in the realms of agriculture and diverse industrial sectors. The company's steadfast dedication to research and development fuels the creation of groundbreaking solutions that address critical health challenges and improve the quality of life for individuals worldwide. At the heart of KREBSBIO's operations lies a diverse portfolio of specialized APIs, each meticulously crafted to meet the exacting demands of the pharmaceutical industry. Renowned for its expertise in steroid intermediates and anti-cholesterol treatments, KREBSBIO produces essential ingredients such as androstenedione, lovastatin, and simvastatin, which serve as building blocks for life-saving medications. These high-quality APIs play a pivotal role in the formulation of pharmaceuticals that combat cardiovascular diseases and hormonal imbalances, empowering healthcare professionals to deliver effective treatments. Driven by an unwavering pursuit of innovation, KREBSBIO continues to expand its horizons, diligently developing a range of novel products that address a spectrum of therapeutic needs. The company's research pipeline encompasses a variety of promising APIs, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine, each designed to combat specific ailments and enhance patient well-being. By constantly pushing the boundaries of pharmaceutical science, KREBSBIO remains at the forefront of the industry, dedicated to providing cutting-edge solutions that improve global health outcomes.
Company Details
Key Leadership
Corporate Events
KREBSBIO Share Price: Frequently Asked Questions
What is the current share price of Krebs Biochemicals & Industries Limited?
Krebs Biochemicals & Industries Limited (KREBSBIO) trades at ₹64.89 on NSE and BSE. Market cap ₹141.35 (Cr). Educational data only.
What is the P/E ratio of Krebs Biochemicals & Industries Limited?
Krebs Biochemicals & Industries Limited has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Krebs Biochemicals & Industries Limited?
Krebs Biochemicals & Industries Limited has a Bull Run score of 11.4/100 based on 25+ financial parameters.
Does Krebs Biochemicals & Industries Limited pay dividends?
Krebs Biochemicals & Industries Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Krebs Biochemicals & Industries Limited?
Krebs Biochemicals & Industries Limited has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Krebs Biochemicals & Industries Limited?
Krebs Biochemicals & Industries Limited has debt-to-equity of N/A.
Is Krebs Biochemicals & Industries Limited a good investment?
Bull Run gives Krebs Biochemicals & Industries Limited a score of 11.4/100. This is not investment advice — consult a SEBI-registered advisor.